PTC Therapeutics (PTCT)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of PTC Therapeutics (PTCT)
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Key Insights
Critical company metrics and information
Share Price
$48.04Market Cap
$3.71 BillionTotal Outstanding Shares
77.13 Million SharesTotal Employees
995Dividend
No dividendIPO Date
June 20, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.ptcbio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $-177.97 Million |
Net Cash Flow | $353.96 Million |
Net Cash Flow From Investing Activities, Continuing | $-317.95 Million |
Net Cash Flow, Continuing | $353.96 Million |
Net Cash Flow From Operating Activities | $-177.97 Million |
Net Cash Flow From Financing Activities | $849.88 Million |
Net Cash Flow From Investing Activities | $-317.95 Million |
Net Cash Flow From Financing Activities, Continuing | $849.88 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $-453.20 Million |
Basic Average Shares | $76.94 Million |
Operating Income/Loss | $-134.36 Million |
Other Operating Expenses | $211.44 Million |
Revenues | $900.66 Million |
Net Income/Loss Attributable To Parent | $-453.20 Million |
Diluted Average Shares | $76.94 Million |
Diluted Earnings Per Share | $5.94 |
Benefits Costs and Expenses | $1.33 Billion |
Net Income/Loss | $-453.20 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations Before Tax | $-425.47 Million |
Costs And Expenses | $1.33 Billion |
Basic Earnings Per Share | $5.94 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Income Tax Expense/Benefit | $27.73 Million |
Research and Development | $531.06 Million |
Income/Loss From Continuing Operations After Tax | $-453.20 Million |
Operating Expenses | $1.04 Billion |
Selling, General, and Administrative Expenses | $292.52 Million |
Income Tax Expense/Benefit, Deferred | $4.01 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Liabilities And Equity | $1.84 Billion |
Other Non-current Assets | $167.14 Million |
Assets | $1.84 Billion |
Current Liabilities | $610.71 Million |
Fixed Assets | $63.17 Million |
Current Assets | $1.28 Billion |
Intangible Assets | $330.37 Million |
Equity Attributable To Parent | $-1.05 Billion |
Liabilities | $2.90 Billion |
Noncurrent Liabilities | $2.29 Billion |
Accounts Payable | $13.29 Million |
Noncurrent Assets | $560.69 Million |
Equity | $-1.05 Billion |
Wages | $46.21 Million |
Other Current Assets | $1.05 Billion |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Current Liabilities | $551.21 Million |
Accounts Receivable | $199.98 Million |
Inventory | $35.67 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.